The Lancet Respiratory Medicine
@LancetRespirMed
Followers
25,448
Following
275
Media
1,815
Statuses
4,417
A unique and international medical journal for respiratory and critical care specialists.
Joined March 2014
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
어린이날
• 504551 Tweets
こどもの日
• 468705 Tweets
子供の日
• 129831 Tweets
#光る君へ
• 96195 Tweets
#鬼滅の刃
• 87124 Tweets
GW最終日
• 66855 Tweets
KRIST SINGTO GOLDENSONG
• 52780 Tweets
Dhoni
• 46129 Tweets
予選突破
• 45928 Tweets
May I Love Patrick🩵
• 25567 Tweets
Thala
• 24716 Tweets
Al Jazeera
• 23873 Tweets
予選通過
• 21237 Tweets
كرم ابو سالم
• 16788 Tweets
連休最終日
• 15880 Tweets
えーりん
• 15699 Tweets
四塩化一黄酸
• 14183 Tweets
GW終わり
• 13778 Tweets
柱稽古編
• 12237 Tweets
Santner
• 11456 Tweets
#アンチヒーロー
• 11395 Tweets
La Salle
• 10048 Tweets
Pinned Tweet
📰May issue out now!
🫁 Read content on septic shock, early mobilisation in the ICU,
#NSCLC
, ventilator associated
#pneumonia
, pulmonary sarcoidosis and more!
📑Editorial on barriers and ethical considerations in lung transplant:
0
9
18
Case Report: Pathological findings of
#COVID19
associated with
#ARDS
Including histological findings of lung, liver, and heart tissue. Provides new insights into the
#pathogenesis
of
#SARSCoV2
-related
#pneumonia
#coronavirus
20
589
692
NEW Series Paper—A tricompartmental model of lung oxygenation disruption to explain pulmonary and systemic pathology in severe
#COVID19
From Prof Dennis McGonagle & colleagues
4
212
469
NEW Series paper—The
#COVID19
puzzle: deciphering pathophysiology and phenotypes of a new disease entity
From Ignacio Rubio & colleagues
2
215
448
To mark 100 years since the 1918 influenza pandemic, we look at progress made since and ask where now?
#influenza100
#pandemicflu
#1918flu
#influenza1918
- register for free access our most highly cited papers on
#pandemicflu
3
134
387
Awake prone positioning of pts w/ hypoxaemic respiratory failure due to
#COVID19
reduces incidence of treatment failure & need for intubation w/o any signal of harm
Meta-trial from the Awake Prone Positioning Meta-Trial Group
5
173
350
Where do we stand in the fight against
#TB
? The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the
#EndTB
era
#LancetTB
#WorldTBDay
@M_Raviglione
@ucl
1
116
309
Marking the
#1918flu
pandemic we're sharing
#influenza
content including our Spotlight on seasonal and pandemic flu
#influenza100
,
@isirvAVG
. Register for free access to The Lancet journals’ most highly cited papers on
#pandemicflu
1
43
212
#Dexamethasone
is associated with a substantial reduction in duration of mechanical
#ventilation
and all-cause 60-day
#mortality
in patients with
#ARDS
New RCT from Jesús ViIlar and colleagues
7
157
232
NEW Viewpoint—The Berlin definition of
#ARDS
: should patients receiving high-flow nasal oxygen be included?
From Prof Michael Matthay & colleagues
1
93
220
NEW Research—Past
#COVID19
infection does not fully protect young people against reinfection
Study from Prof Stuart Sealfon & colleagues
2
161
202
NEW Research— Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early
#COVID19
RCT from Mona Bafadhel & colleagues
4
107
178
#Asthma
and
#immunology
: a call for papers for AAAAI! See full details of the papers we're seeking, and how to submit:
2
61
166
NEW Comment—Rational use of face masks in the
#COVID19
pandemic
S Feng et al compare face mask use recommendations by different health authorities & call for governments and public health agencies to make rational recommendations on appropriate use
6
153
172
NEW Research—Lenzilumab significantly improved survival without invasive mechanical ventilation in hospitalised patients with
#COVID19
LIVE-AIR trial from Prof Zelalem Temesgen & colleagues
15
64
159
NEW research: Awake prone positioning is feasible and improves oxygenation in patients with respiratory failure due to
#COVID19
-related
#pneumonia
.
From Giuseppe Foti & colleagues
3
95
153
NEW Series paper—Respiratory sequelae of
#COVID19
: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation
From
@SallySingh_
and colleagues
The first in a Series of three papers about
#PASC
#longCOVID
9
89
154
Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study
#LIVES2018
#ESICM2018
1
64
144
NEW: Clinical course and outcomes of critically ill patients with
#SARSCoV2
pneumonia in Wuhan, China: a single-centered, retrospective, observational study
#COVID19
#Coronavirus
4
127
136
In patients with mild-to-mod
#COVID19
managed without hospital admission, azithromycin + SOC did not reduce the risk of subsequent hospital admission or death
Read the ATOMIC2 trial here , being presented at
#ECCMID2021
by lead author Tim Hinks
@HinksLab
5
112
142
#Asthma
#Immunology
Call for papers for
#AAAAI2019
#AAAAI
Details, incl how to submit available here -->
1
51
126
Send us your respiratory medicine and critical care research. We are looking for research that will change clinical practice or current thinking for our
#ERS
special issue
#RespiratoryHealth
#CriticalCare
#RespiratoryMedicine
5
89
132
Send us your high-quality research on
#CysticFibrosis
for our
@ECFSConference
CF special issue
2
60
128
NEW Health-Care Development:
#Tracheostomy
in the
#COVID19
era: global and multidisciplinary guidance
From Prof David J Feller-Kopman & colleagues
4
67
124
Post-acute sequelae of
#COVID19
: a growing public health crisis on a global scale that demands a focused, well-resourced, and patient-centred response
Find out more in a new
@LancetRespirMed
Series
#PASC
#longCOVID
#postCOVID
12
65
117
Our April issue includes a new phase 1
#RandomisedControlledTrial
of a novel
#TB
#vaccine
. Free to view with registration.
#WorldTBDay
#LancetTB
@satviuct2017
@AfricanVaccine
0
19
96
NEW Research—Continued enteral nutrition until extubation in critically ill patients in the ICU is a practice that could be safe to implement and be associated with potential benefits
Read the trial from Mickaël Landais & colleagues here:
#SCCM2023
2
46
115
Correspondence regarding patients with
#hypertension
and
#diabetes
mellitus and
#COVID19
from Michael Roth and colleagues
(1/4)
6
60
106
Effectiveness of WHO’s pragmatic screening algorithm for
child contacts of
#tuberculosis
cases in resource-constrained
settings
#WorldTBDay
#LancetTB
@StanfordMed
0
23
100
See an Original Investigation from
@JAMA_current
on the definition of post-acute sequelae of
#SARSCoV2
infection
And the first paper in a
@LancetRespirMed
Series on the post-acute sequelae of
#COVID19
#PASC
#longCOVID
#postCOVID
0
55
107
NEW Comment: F Taccone et al on hydroxychloroquine & critically ill
#COVID19
pts
“Whether antimalarial drugs could be effective in changing the disease course in pts with severe COVID-19—in particular, in cases requiring ICU admission—remains unknown"
1
73
109
NEW Research—Characterisation of the first 250 000 hospital admissions for
#COVID19
in Brazil
From Otavio Ranzani & colleagues
0
27
103
NEW Research—In community-treated patients, the effect of colchicine on
#COVID19
-related clinical events was not significant
The COLCORONA study from Prof Jean-Claude Tardif & colleagues
3
61
101
On
#WorldPneumoniaDay
, Stefano Aliberti and colleagues call for the establishment of an International Pneumonia Network to improve awareness and funding for
#pneumonia
@AlibertiStefano
@PneumoniaDay
#StopPneumonia
#WPD2018
2
43
96
The
#cytokinestorm
in
#COVID19
: "Targeting thrombin, coagulation factor Xa, or PAR-1, might be an attractive approach to reduce
#SARSCoV2
microthrombosis, lung injury, and associated poor outcomes"
NEW Correspondence from R Jose & A Manuel
1
75
100
Interstitial Lung Disease 2021
A Series of papers on
#ILD
from
@TheLancet
and
@LancetRespirMed
, published to coincide with
#ERS2021
, is now live
#ERSCongress
@EuroRespSoc
@KerriBerriKerri
1
26
98
Long-term developmental effects of withholding parenteral nutrition for 1 week in the
#paediatric
intensive care unit: 2-year follow-up of PEPaNIC
Register now for free
@LancetRespirMed
&
@TheLancet
content from
#ERSCongress
3
36
97
NEW Research—Hospitalised
#COVID19
patients in UK who received inhaled form of interferon beta-1a were more likely to recover & less likely to develop severe symptoms than those who received placebo: phase 2 RCT
2
38
95
There is an urgent need for unification of terminology for the sequelae of
#SARSCoV2
infection to ensure that research is directed towards and translated into interventional trials to improve outcomes
NEW Comment—
#LongCOVID
: aiming for a consensus
2
51
94
NEW Viewpoint—A2BCD: a concise guide for
#asthma
management
From Prof Marek Lommatzsch & colleagues
0
42
93
NEW Series—Interleukin-6 receptor blockade in patients with
#COVID19
: placing clinical trials into context
From Federico Angriman & colleagues
0
46
91
Anti-inflammatory effects of roflumilast in
#COPD
(ROBERT): a 16-week, randomised, placebo-controlled trial
Register now for free
@LancetRespirMed
&
@TheLancet
content from
#ERSCongress
5
36
88
#Influenza100
: read a selection of
@TheLancet
journals’ most highly cited
#influenza
articles and stay connected with us to receive updates and
#flu
content
#pandemicflu
#1918flu
#influenza1918
1
30
78
NEW— <1/4 of
#COVID19
cases shed infectious virus before symptom onset; after a 5-day self-isolation period from symptom onset, 2/3 of cases would still be infectious, but with reduced infectious viral shedding
Study from Seran Hakki & co
2
44
88
NEW—Baricitinib did not improve the composite primary endpoint of progression to NIV,
high-flow O2, IMV, or death; however, it did reduce 28-day all-cause mortality by 38·2% vs placebo (HR 0·57 [95% CI 0·41–0·78])
Read the COV-BARRIER study:
#ISICEM2021
2
47
86
NEW Research—Anakinra did not improve outcomes in patients with mild-to-moderate
#COVID19
pneumonia
CORIMUNO-ANA-1 trial from Xavier Mariette & colleagues
1
57
83
NEW research—Morphine for treatment of
#cough
in
#IdiopathicPulmonaryFibrosis
(PACIFY COUGH)
From Philip L Molyneaux & colleagues:
3
42
87
A new individual participant data
#MetaAnalysis
assesses treatments for people with isoniazid-resistant
#TB
.
#WorldTBDay
#LancetTB
@mcgillu
0
12
76
Our April issue is
#tuberculosis
theme for
#WorldTBDay
. Read about the latest developments in
#TB
and progress towards
#EndTB
#LancetTB
0
17
72
NEW Research—Cumulative exposure to higher intensities of
#mechanicalventilation
was harmful, even for short durations
Prospective cohort study from Eddy Fan & colleagues on time-varying intensity of mechanical ventilation and mortality
1
43
81
Linked Comment—Awake prone positioning in
#COVID19
: is tummy time ready for prime time?
From Jason Weatherald & colleagues
On the meta-trial
3
32
79
James Chalmers and Sanjay H Chotirmall propose a reassessment of the current approach to
#bronchiectasis
in this Series …
@dundeeuni
@NTUsg
2
30
76
NEW—Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation
From the
@PHOSP_COVID
Collaborative Group
#longCOVID
@REvans_Breathe
@LouiseVwain
3
54
78
On
#WorldPneumoniaDay
, ICYMI our news piece from earlier this year on the
@resinstudy
report Sizing Up Pneumonia Research highlighted the lack of funding for
#pneumonia
@PneumoniaDay
#StopPneumonia
#WPD2018
0
19
65
New Spotlight on
#COVID19
infection in children from Dr Ian P Sinha and colleagues
Includes info on a national guideline for management of children with
#COVID19
from
@RCPCHtweets
0
41
73
NEW Research—In suspected
#COVID19
in the community, doxycycline was not associated with clinically meaningful reductions in time to recovery or hospital admissions or deaths, and should not be used as a routine treatment
Read the PRINCIPLE trial here
3
39
74
NEW Comment—
#SARSCoV2
antigen testing: weighing the false positives against the costs of failing to control transmission
From Elizabeth Fearon & colleagues
0
33
69
NEW Research—A single dose of the FINLAY-FR-1A vaccine against
#SARSCoV2
strengthened the pre-existing natural immunity, with excellent safety profile
RCT from
@OchoaAzze
& colleagues
1
40
68
NEWS: Omicron variant and booster COVID-19 vaccines
14
43
69
NEW Research—Heterologous ChAdOx1 nCov-19–BNT162b2 immunisation w/ 10–12-week interval is well tolerated & improves immunogenicity vs homologous ChAdOx1 nCov-19 vax w/ 10–12-week interval & BNT162b2 vax w/ 3-week interval
Study from Prof Sander & co
3
37
68
NEW Personal View—Confronting
#COVID19
-associated
#cough
and the
#postCOVID
syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses
From Prof Kian Fan Chung and colleagues
0
34
69
#Lymphopenia
is a common feature of
#COVID19
and might be a critical factor associated with disease severity and mortality
3
36
57
NEW Spotlight—Why has the incidence of
#tuberculosis
not reduced in London during the
#COVID19
pandemic?
From
@danlewer
& colleagues
3
38
64
The field of
#pulmonaryhypertension
has been transformed by advances in understanding of pathophysiological mechanisms and the development of a wide range of
#therapeutic
options
Find out more in a new
@LancetRespirMed
Series
#PH
#PAH
#CTEPH
#COPD
#ILD
4
31
66
NEW Series paper—Understanding clinical and biological heterogeneity to advance precision medicine in
#PARDS
From
@Martin_Kneyber
& colleagues:
The third in a Series of papers from
@TheLancet
and
@LancetRespirMed
on
#ARDS
2
22
65
"Lung damage from bronchiectasis is irreversible and treatment options are scarce. Until recently, most trials have been negative."
Read our Editorial on
#bronchiectasis
here:
2
27
66
Call for papers - we're seeking high quality studies in the field of cystic fibrosis. Submit your research here:
#CysticFibrosis
3
33
59
The December issue of
@LancetRespirMed
is now online!
Access it here:
#COVID19
,
#ILD
,
#ecigerettes
, and more...
1
26
61
NEW Research—Point-of-care serological assays for delayed
#SARSCoV2
case identification among health-care workers in the UK
From Capt Scott J C Pallett & colleagues
1
29
61
Our NEW MAY ISSUE is here: including content on
#COPD
, primary ciliary dyskinesia, prematurity-associated lung disease, and much more!
Check it out here:
1
38
60
Duet of papers: microbiome and respiratory disease/critical illness
0
71
55
NEW—Updated, long-term data from the CROWN study show durable benefit of lorlatinib vs crizotinib in pts w/ treatment-naive, ALK-positive
#NSCLC
From Prof Benjamin Solomon & colleagues
4
34
59
Interesting podcast on
#pleural
disease from
@ERSpublications
.
Read our Review on
#malignant
#pleural
#effusion
management: keeping the flood gates shut by
Prof Najib M Rahman and colleagues here
0
32
59
NEW Research—
#Tocilizumab
is not an effective therapeutic option for adults with
#COVID19
, although there might be a role for it in adults with severe
#COVID19
in India
From Arvinder Soin & colleagues
With accompanying podcast:
0
32
59
The first issue of
@LancetRespirMed
for 2021 is here
Includes original research on
#RSV
,
#asthma
, pulmonary embolism,
#IPF
, and systemic sclerosis-ILD, and much much more!
0
16
59
Home oxygen probably makes little or no difference to 3-year mortality in pts with
#COPD
and moderate hypoxaemia
Systematic review & meta-analysis from Yves Lacasse & colleagues
2
28
57
NEW Comment—Association of SARS-CoV-2 infection and persistence with
#longCOVID
From Scott J Tebbutt & colleagues
1
34
55
Comment: Deep learning and the evaluation of
#pulmonary
fibrosis
Register now for free
@LancetRespirMed
&
@TheLancet
content from
#ERSCongress
0
27
53
CORRESPONDENCE: Effectiveness of COVID-19 vaccines to prevent
#longCOVID
: data from Norway
Data demonstrate real-world effectiveness of COVID-19 vaccines to prevent long COVID symptoms and post-COVID thromboembolic and cardiovascular complications
1
32
60
NEW Podcast—On the STOIC trial of budesonide for early
#COVID19
, with Mona Bafadhel
PODCAST:
STUDY:
4
28
53
NEW Research—
@ISARIC4C
Deterioration model for adults hospitalised with
#COVID19
can predict clinical deterioration and inform decision making
From Rishi Gupta and colleagues
@CCPUKstudy
@ucl
1
28
53
A stay in the
#ICU
can have long-lasting physical and psychological consequences. This month’s cover story is about the InS:PIRE programme in Glasgow, which helps people to get back on their feet after
#CriticalCare
. .
@GRIICUQI
@taraquasim
4
46
53
NEW Research—Early mobilisation might improve long-term cognitive impairment in ICU survivors after MV, but the increased risk of adverse events in the intervention group should be noted
Read the RCT from Bhakti Patel & colleagues here:
#SCCM2023
2
26
52
NEW Research—Sleep disturbance after hospitalisation for
#COVID19
is associated w/ dyspnoea, anxiety, & muscle weakness. Targeting sleep disturbance might be beneficial in treating the
#postCOVID19condition
From Callum Jackson & colleagues
#ECCMID
0
19
51
Attending
@ERSTalk
#ERSCongress
in Paris? You are invited to join our Editor Emma Grainger and a panel of experts to discuss new insights in diagnosis and treatment of
#bronchiectasis
Read a new Series with
@TheLancet
0
26
50
Three-quarters of COPD cases are linked to childhood risk factors that are exacerbated in adulthood - new research
#COPD
#asthma
@unimelb
@MonashUni
0
69
51
The final issue of
@LancetRespirMed
for 2020 is live!
Includes original
#COVID19
research:
1) COVID-19 in UK homeless population
2) Pathophysiology of COVID-19-associated
#ARDS
And much, much more
1
19
50